Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
alanine aminotransferase/proljev
Veza se sprema u međuspremnik
6 rezultatima
Probiotics in Metformin Intolerant Patients With Type 2 Diabetes
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
The optimal daily dose of metformin is thought to be 2000 mg, however patients with metformin intolerance cannot reach this target dose. Participate in this study are metformin intolerant. Metformin intolerant patients have been defined as those not able to be treated with the metformin daily dose
Alectinib in Combination With Bevacizumab in ALK Positive NSCLC
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
BACKGROUND The burden of Lung Cancer Lung cancer remains the most lethal malignancy worldwide, claiming more lives compared to any other malignant disease in both developed and developing countries, as well as globally. Although some countries have accomplished a decrease in incidence rates, most
Prevention of Phototoxicities in Patients Undergoing Vemurafenib Treatment
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
Vemurafenib is an anti-cancer treatment indicated as monotherapy in the treatment of adult patients with non-resectable or metastatic melanoma carrying a BRAF V600 mutation.
Cobimetinib is indicated in combination with Vemurafenib in the treatment of adult patients with non-resectable or metastatic
Comparison of the Effectiveness and Tolerability of Exenatide Once-weekly Compared to Basal Insulins
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
Background: In January 2012, the US Food and Drug Administration approved a once-weekly form of exenatide, Bydureon, for the treatment of type 2 diabetes mellitus. Evidence from clinical trials suggested that Bydureon improves glucose control with low risk of hypoglycemia. Bydureon does not require
Subanalyses of Elderly Type 2 Diabetes Patients or Type 2 Diabetes Patients With Renal Impairment
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
Background: In January 2012, the US Food and Drug Administration approved a once-weekly form of exenatide, Bydureon, for the treatment of type 2 diabetes mellitus. Evidence from clinical trials suggested that Bydureon improves glucose control with low risk of hypoglycemia. Bydureon does not require
Comparison of Cost-effectiveness of Continuation Maintenance Therapy With Six Cycles of Pemetrexed Versus Pemetrexed Until Disease Progression for Metastatic Non-squamous Non-small-cell Lung Cancer
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
Inclusion criteria:
1. Males and females ≥ 20 years of age
2. ECOG performance status of 0-1
3. Histologically or cytologically verified non-squamous NSCLC
4. Stage IV disease, as defined by American Joint Committee on Cancer 7th edition staging, prior to first-line or second-line chemotherapy with
Najkompletnija baza ljekovitog bilja potpomognuta znanošću
- Radi na 55 jezika
- Biljni lijekovi potpomognuti znanošću
- Prepoznavanje bilja slikom
- Interaktivna GPS karta - označite bilje na mjestu (uskoro)
- Pročitajte znanstvene publikacije povezane s vašom pretragom
- Pretražite ljekovito bilje po učincima
- Organizirajte svoje interese i budite u toku s istraživanjem vijesti, kliničkim ispitivanjima i patentima
Upišite simptom ili bolest i pročitajte o biljkama koje bi mogle pomoći, unesite travu i pogledajte bolesti i simptome protiv kojih se koristi.
* Svi podaci temelje se na objavljenim znanstvenim istraživanjima
